Literature DB >> 23393543

Rituximab as a possible cause of posterior reversible encephalopathy syndrome.

Ahmed Imran Siddiqi1.   

Abstract

A 66-year-old woman presented with new onset generalised tonic-clonic seizures following her first dose of chemotherapy comprising Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin and Prednisolone (R-CHOP) 10 days earlier for non-Hodgkin's lymphoma. On admission, computed tomography (CT) scan of the cranium showed no abnormality. The CT was repeated within 48 hours as the patient developed status epilepticus and papilledema; the repeat scan showed characteristics of posterior reversible encephalopathy syndrome (PRES). Association of rituximab with this condition was suspected as there was no recurrence of PRES after receiving two more cycles of CHOP without rituximab. Contrary to previously published case reports, this patient had a delayed clinical presentation.

Entities:  

Keywords:  Posterior reversible encephalopathy syndrome; chemotherapy; seizures

Year:  2011        PMID: 23393543      PMCID: PMC3562911          DOI: 10.4066/AMJ.2011.627

Source DB:  PubMed          Journal:  Australas Med J        ISSN: 1836-1935


  13 in total

1.  Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica.

Authors:  Alejandro Sánchez-Carteyron; Raquel Alarcia; José Ramón Ara; Jesús Martín
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

2.  A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion.

Authors:  C P Mavragani; P G Vlachoyiannopoulos; N Kosmas; I Boletis; A G Tzioufas; M Voulgarelis
Journal:  Rheumatology (Oxford)       Date:  2004-11       Impact factor: 7.580

Review 3.  Etiology and pathogenesis of preeclampsia: current concepts.

Authors:  G A Dekker; B M Sibai
Journal:  Am J Obstet Gynecol       Date:  1998-11       Impact factor: 8.661

4.  Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI.

Authors:  H Ay; F S Buonanno; P W Schaefer; D A Le; B Wang; R G Gonzalez; W J Koroshetz
Journal:  Neurology       Date:  1998-11       Impact factor: 9.910

5.  Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings.

Authors:  M T Russell; A S Nassif; E D Cacayorin; E Awwad; W Perman; F Dunphy
Journal:  Magn Reson Imaging       Date:  2001-01       Impact factor: 2.546

6.  Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases.

Authors:  R B Schwartz; K M Jones; P Kalina; R L Bajakian; M T Mantello; B Garada; B L Holman
Journal:  AJR Am J Roentgenol       Date:  1992-08       Impact factor: 3.959

7.  Cyclophosphamide-induced reversible posterior leukoencephalopathy syndrome.

Authors:  Maria Jose Abenza-Abildua; Blanca Fuentes; Domingo Diaz; Aranzazu Royo; Teresa Olea; Maria Jose Aguilar-Amat; Exuperio Diez-Tejedor
Journal:  BMJ Case Rep       Date:  2009-05-25

8.  Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome.

Authors:  Y Ito; Y Arahata; Y Goto; M Hirayama; M Nagamutsu; T Yasuda; T Yanagi; G Sobue
Journal:  AJNR Am J Neuroradiol       Date:  1998-03       Impact factor: 3.825

9.  Hypertensive encephalopathy. Magnetic resonance imaging demonstration of reversible cortical and white matter lesions.

Authors:  R A Hauser; D M Lacey; M R Knight
Journal:  Arch Neurol       Date:  1988-10

10.  A case of gemcitabine and cisplatin associated posterior reversible encephalopathy syndrome.

Authors:  Eun Jin Kwon; Se Won Kim; Kwang Ki Kim; Hyung Suk Seo; Do Yeun Kim
Journal:  Cancer Res Treat       Date:  2009-03-31       Impact factor: 4.679

View more
  4 in total

Review 1.  Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.

Authors:  Joan How; Margaret Blattner; Susan Fowler; Andrea Wang-Gillam; Suzanne E Schindler
Journal:  Neurologist       Date:  2016-11       Impact factor: 1.398

2.  Chronic enteroviral meningoencephalitis in a patient on rituximab for the treatment of psoriatic arthritis: A case report and brief literature review.

Authors:  Roberto Tellez; Allison M Lastinger; Jeffery P Hogg
Journal:  IDCases       Date:  2019-05-09

Review 3.  Rituximab in treatment of anti-GBM antibody glomerulonephritis: A case report and literature review.

Authors:  Mayu Uematsu-Uchida; Takehiro Ohira; Shigeki Tomita; Hiroshi Satonaka; Akihiro Tojo; Toshihiko Ishimitsu
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

Review 4.  Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention.

Authors:  Benxia Zhang; Xue Li; Tao Yin; Diyuan Qin; Yue Chen; Qizhi Ma; Pei Shu; Yongsheng Wang
Journal:  J Oncol       Date:  2022-01-18       Impact factor: 4.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.